The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy (a phase 3 diagnostic study).
 
Michael A. Gorin
No Relationships to Disclose
 
Eva Lengyelova
Employment - Clarity Pharmaceuticals
Leadership - Clarity Pharmaceuticals
Stock and Other Ownership Interests - Clarity Pharmaceuticals
 
Luke Nordquist
No Relationships to Disclose
 
Glynn Morrish
Consulting or Advisory Role - Clarity Pharmaceuticals
 
Othon Gervasio
Employment - Clarity Pharmaceuticals
Leadership - Clarity Pharmaceuticals
Stock and Other Ownership Interests - Clarity Pharmaceuticals
 
Robert M. Miller
Employment - Clarity Pharmaceuticals; Hubro Therapeutics; Scancell Ltd.
Stock and Other Ownership Interests - Hubro Therapeutics (Inst)
Consulting or Advisory Role - Clarity Pharmaceuticals; Scancell Ltd.
Travel, Accommodations, Expenses - Hubro Therapeutics; Scancell Ltd.
 
Neal D. Shore
Employment - GenesisCare
Leadership - Alessa Therapeutics; Photocure
Stock and Other Ownership Interests - Alessa Therapeutics; Photocure
Consulting or Advisory Role - Abbvie; Accord Research; AIkido Pharma; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; FerGene; Ferring; Fize Medical; Genesis Cancer Care; Genzyme; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring